Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 57

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Hormone receptor positive HER2 negative breast cancer+1

Not recruiting

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:BOOG Study Center B.V.

Gastric cancer+5

Not recruiting

Study of nivolumab alone or combined with ipilimumab for patients with advanced solid tumors (breast, gastric, pancreatic, lung, bladder, or ovarian cancer)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol Myers Squibb International Corporation

Breast cancer metastatic

Not recruiting

Study of Disulfiram and Copper for Patients with Metastatic Breast Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Disulfiram
  • Sponsor:Univerzita Palackeho V Olomouci

HER2 positive breast cancer

Not recruiting

Study on Chemotherapy-Free Treatment with Trastuzumab, Pertuzumab, and T-DM1 for Patients with HER2-Positive Early-Stage Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Medica Scientia Innovation Research S.L.

Breast cancer

Not recruiting

Study on Atorvastatin for Patients with Early Breast Cancer

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Region Midtjylland

Breast cancer metastatic

Not recruiting

Study on the Safety and Effects of Zanidatamab, Palbociclib, and Fulvestrant for Patients with Advanced or Metastatic HER2-Positive, HR-Positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Breast cancer female

Not recruiting

Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Unicancer

Prostate cancer

Not recruiting

Study on Enzalutamide for Patients with Localized Prostate Cancer Undergoing Robotic-Assisted Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Asociacion Instituto De Investigacion Sanitaria Biobizkaia

Triple negative breast cancer+1

Not recruiting

Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eribulin
  • Sponsor:Medica Scientia Innovation Research S.L.

Endometrial sarcoma

Not recruiting

Study on Stopping or Continuing Anastrozole, Letrozole, and Exemestane for Patients with Advanced or Metastatic Low-Grade Endometrial Stromal Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Centre Leon Berard

Obesity+1

Not recruiting

Study on Testosterone Undecanoate for Muscle Strength and Mass in Men with Obesity and Low Testosterone Undergoing Bariatric Surgery

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Testosterone Undecanoate
  • Sponsor:Esbjerg Og Grindsted Sygehus

Prostate cancer

Not recruiting

Study of Apalutamide for Patients with High-Risk Prostate Cancer After Prostate Removal

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Universitaet Muenster

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.